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Summary This study examined the pathophysiological role of parathyroid hormone-related protein (PTHrP)
in humoral hypercalcaemia of malignancy (HHM). Seven human tumour xenografts were analysed in nude
mice; five tumours (KEsC-2, oesophageal carcinoma; FA-6, pancreatic carcinoma; SEKI, melanoma; Lu-65A
and Lu-61, lung carcinomas) were associated with hypercalcaemia and two tumours (MIA PaCa-2, pancreatic
carcinoma; PLC/PRF/5, hepatocellular carcinoma) with normocalcaemia. Northern blot analyses, radio-
immunoassay and bioassay confirmed the synthesis of PTHrP-like peptides by all five tumours associated with
hypercalcaemia, but not by the two associated with normocalcaemia. These observations indicated a very close
relationship between the production of PTHrP and the development of HHM. Gel filtration studies of three
tumour tissue extracts revealed at least two different molecules with both PTHrP-like immunological and
biological activities. One peak eluted at a position between PTHrP (1-141) and cytochrome C and the other at
a position identical to cytochrome C. These results suggest that PTHrP molecules with a molecular size equal
to or greater than cytochrome C participate as causative agents of HHM. All five tumour xenografts caused
hypercalcaemia when grown to a size of 1.5 g in nude mice. Under cell culture conditions, four original cell
lines, KEsC-2, FA-6, SEKI and Lu-65A secreted 450.0, 45.0, 3.6 and 3.0 pmol of immunoreactive PTHrP/
1.5 x 109 cells (approximately equivalent to 1.5 g wet weight) 24 h- ' into their respective culture media. Since a
subcutaneous infusion of 100 pmol 24 h- of PTHrP (1-34) into nude mice was sufficient to induce significant
hypercalcaemia, we speculate that PTHrP alone released from tumour cells could induce hypercalcaemia at
least in the case of KEsC-2, and possibly in FA-6. With regard to other tumours associated with hypercal-
caemia, further examination of PTHrP and other compounds with bone-resorbing activity in these transplant-
able tumours is required to obtain a better understanding of this morbidity.
Humoral hypercalcaemia of malignancy (HHM) is a morbid-
ity defined as the solid tumour-associated hypercalcaemia
induced by the production of hypercalcaemic factor(s) by the
tumour cells (Yendt, 1972; Stewart et al., 1980). Although
several hypercalcaemic factors have been presented as the
causative agents responsible for this morbidity, a newly-
identified calcium-elevating protein, parathyroid hormone-
related protein (PTHrP), is now considered to be the major
agent responsible for HHM (Suva et al., 1987; Mangin et al.,
1988). Our recent clinical studies on surgical and autopsy
specimens obtained from patients presenting with HHM
revealed a very close relationship between the production of
PTHrP and the development of HHM, suggesting that
PTHrP plays a key role in the pathogenesis of HHM (Honda
et al., 1988a; Tsuchihashi et al., 1990). Further support for
this conjecture comes from recent studies reporting
significantly elevated plasma PTHrP levels in patients with
HHM (Budayr et al., 1989a; Burtis et al., 1990).
In the present study, five tumour xenografts, with hyper-
calcaemia-inducing activities, were analysed to determine
whether they produced PTHrP. Since all five tumours pro-
duced PTHrP, the amount of PTHrP produced by and
released from tumour cells and the characteristics of these
PTHrP molecules were assessed using PTHrP radioimmuno-
assay (RIA) and bioassay. These human tumour xenografts
in nude mice may serve as a useful experimental model to
clarify the actual contribution of PTHrP and other factors
with bone-resorbing activity to HHM.
Materials and methods
Materials
Synthetic human PTHrP(1-34) and (1-37) were purchased
from Peninsula Lab. Inc. (Belmont, CA, USA). Synthetic
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human parathyroid hormone (PTH) (1-34) and (1-84) were
from Peptide Institute Inc. (Osaka, Japan). Chemical syn-
thesis of PTHrP(1-34) analogues with deletions at the
amino-terminal portion, PTHrP(7-34)NH2, (10-34)NH2,
(15-34)NH2 and (20-34)NH2 were reported previously
(Nagasaki et al., 1989). Recombinant human PTHrP(1-141)
was kindly provided by Tonen Co. Ltd. (Saitama, Japan); the
synthesising methods of this recombinant peptide will be
reported elsewhere (Urakami, M. et al., manuscript in pre-
paration). Briefly, the chemically synthesised gene encoding
PTHrP(1-141) was expressed in E. coli. After purification of
the recombinant protein to homogeneity, peptide sequence
analyses revealed that at least the 35 amino-terminal amino
acid residues were identical to human PTHrP(1-141). When
analysed by a bioassay using ROS 17/2.8 cells (described
below), this protein possessed 1.6 times more biological
activity than synthetic human PTHrP(1-34). The other
materials purchased were: Activated CH-Sepharose 4B,
NAP-25 column (1.5 x 5.0cm) prepacked with Sephadex
G-25 medium, Sephadex G-75 fine, rRNA 28S and 18S (calf
liver) from Pharmacia P-L Biochemicals (Uppsala, Sweden);
Na 1251I and '251I-human albumin from New England Nuclear
(Boston, MA, USA); Cyclic AMP RIA kit from Yamasa
Shoyu Co. Ltd. (Chiba, Japan).
Human tumour cell lines and their xenografts in nude mice
Six human tumour cultured cell lines were studied: KEsC-2
(squamous cell oesophageal carcinoma) formerly designated
as 'KN-13' (Honda et al., 1988b), FA-6 (anaplastic pancrea-
tic carcinoma) (Nagata et al., 1989), SEKI (melanoma)
(Shimoyama, 1975), Lu-65A (giant cell lung carcinoma),
MIA PaCa-2 (pancreatic adenocarcinoma) and PLC/PRF/5
(hepatocellular carcinoma). KEsC-2 and FA-6 were examin-
ed because they were established from patients presenting
with HHM. SEKI was established at the National Cancer
Center Research Institute (Tokyo, Japan) and Lu-65A was
provided by the Japanese Cancer Research Resources Bank
(Tokyo, Japan). Regarding these two cell lines, patient in-
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formation was not available; but, nude mice bearing these
tumour cells developed hypercalcaemia. MIA PaCa-2 and
PLC/PRF/5 were used as controls; the former was purchased
from the American Type Culture Collection (Rockville, MD,
USA) and the latter was provided by the Japanese Cancer
Research Resources Bank. All of these cell lines were main-
tained at 37°C under 5% C02: 95% air in 75 cm2 plastic
tissue culture flasks using the original medium described in
the references and the catalogues. The culture media for all
these cell lines were supplemented with 10% foetal bovine
serum (FBS), penicillin (50 units ml-') and streptomycin
(50fg ml-') (GIBCO Laboratories, Grand Island, NY,
USA).
Five-week-old female Balb/CA-nu/nu nude mice were
obtained from Japan Charles River Co. Ltd. (Kanagawa,
Japan). Tumour xenografts in nude mice were produced by
subcutaneous inoculation of about I x 107 cells of these cell
lines into a flank region. All tumours were successfully trans-
planted to nude mice. Approximately 30 mg of the respective
tumour specimens was further transplanted into the flank
region of the animals. Additionally, a tumour xenograft to
nude mice of squamous cell lung carcinoma (Lu-61) was also
examined. This tumour was established from a patient pre-
senting with HHM (Kameya et al., 1982). In vitro culture of
this tumour xenograft was not successful. Frequent observa-
tions of the tumour-bearing mice were performed to prevent
death due to hypercalcaemia.
The tumour size was measured once a week with a slide
caliper, and tumour weight was calculated according to Ove-
jera et al. (1978). When the size of the tumours reached
approximately 1.5 g, blood was obtained for determining
plasma calcium. Then, the tumour tissues were removed from
animals. Immediately after removal, the tissues were cut into
pieces; about 0.5 g was stored at - 80°C for determining the
tissue concentrations of immunoreactive (IR-) and bioactive
(BIO-) PTHrP and the rest in liquid nitrogen for Northern
blot analyses.
Plasma calcium levels in nude mice
Plasma calcium concentrations were measured as described
by Nagasaki et al. (1989).
Northern blot analyses
Poly(A)+ RNA extraction, gel electrophoresis and Northern
blot hybridisation were performed by the previously reported
method (Honda et al., 1988a,b). For detecting PTHrP
mRNA, a previously described synthetic DNA probe, corre-
sponding to the 17 amino acids of PTHrP (62-78) was used.
To determine the integrity of tissue poly(A)+ RNA extracted
and to compare the amount of poly(A)+ RNA from each
tissue, the levels of human P-actin mRNA were examined
(Honda et al., 1988a).
Tissue extractionfor PTHrP
Tissues were extracted by the previously reported method
(Stewart et al., 1983; Gkonos et al., 1984; Weir et al., 1988;
Tsuchihashi et al., 1990) with minor modifications. Briefly,
0.5 g of frozen tissue was homogenised in 0.1 M Tris-HCl,
pH 7.4, followed by centrifugation at 28,000g. The pellet was
extracted with an 8 M urea/0.1 M cysteine/0.2 M HCI solution
at a concentration of 2 ml g-' wet weight; the extract was
recentrifuged and the supernatant collected. To remove urea,
the supernatant was applied to a NAP-25 column and the
PTHrP-like activity was eluted with a 3.5 ml wash of 1 M
acetic acid. When the PTHrP concentration in the super-
natant and the eluate from NAP-25 column were examined
by RIA, the recovery rate was always estimated to be more
than 90% in all tumour tissues examined. The eluate was
divided into two parts and lyophilised. Each lyophilised sam-
ple was reconstituted with 1 ml of standard diluent for the
RIA or the bioassay medium; 0.1 ml of the former or 0.2 ml
of the latter were used for RIA or bioassay, respectively. All
procedures were performed at 4°C.
Collection and extraction ofculture media
After the tumour cells had grown to subconfluence in 75 cm2
flasks, they were washed with fresh medium and cultured in
25 ml of their culture medium with 10% FBS for 24 h. The
media were collected and clarified by centrifugation at 500g
for 5 min. The cell number was counted with a haemocyto-
meter. The media were extracted using immune-affinity
chromatography by coupling 50 lAl of guinea-pig anti-PTHrP
antiserum, NCC-PTHrP-GP-030104, to 1 g of Activated CH-
Sepharose 4B. This antibody had almost identical charac-
teristics to the RIA antibody when assessed by PTHrP
(1-141) and its fragments (data not shown). Culture media
(1Oml) was applied to the column (0.7 x 1.5 cm) and the
bound material collected by methods reported previously
(Maruno et al., 1989). When fresh culture media was supple-
mented with 0.02 and 1.0 pmol of PTHrP(1 -34) and PTHrP
(1-141) and column extracted, the recovery rates (mean+
s.d, n = 3) were 85.0 ± 10.0 and 73.0 ± 2.3%, and 99.0 ± 4.6
and 93.0 ± 10.0%, respectively.
PTHrP RIA andbioassay
The PTHrP RIA was performed by the previously reported
method (Tsuchihashi et al., 1990) with minor modifications.
An anti-PTHrP(1-34) rabbit antiserum, NCC-PTHrP-R-
030301, was used at a final dilution of 1:60,000 (total incuba-
tion volume, 0.7 ml). Recombinant PTHrP(1-141) was used
as the assay standard and PTHrP(I-34) as the tracer. The
specificity of this RIA was further examined with several
PTHrP analogues described above.
PTHrP biological activity was assessed by measuring cyclic
AMP production in a PTH-responsive rat osteosarcoma cell
line (ROS 17/2.8) (Nagasaki et al., 1989). All specimens were
assayed in duplicate and the results were expressed as percent
of the amount of cyclic AMP with respect to basal (medium
alone) levels.
Gelfiltration studies
Extracted samples were chromatographed on Sephadex G-75
(1.0 x 56.0 cm) which was equilibrated and eluted with 1 M
acetic acid (Tsuchihashi et al., 1990). The samples were
supplemented with '25I-human albumin and Na'25I. The col-
umn was also calibrated with PTHrP(1-141) (Mr, 16,043),
cytochrome C (Mr, 12,384) and PTHrP(1-34) (Mr, 4,017).
Statistics
Statistical analyses were performed by the Student's t test.
Results
PTHrP RIA
The amounts of synthetic PTHrP(l -141) which inhibited
labelled antigen binding by 10 and 50% in this RIA system
were 0.0053 and 0.026 pmol tube-', respectively, resulting in
sample concentrations of 53 pmol 1' and 260 pmol 1-'.
Intra- and inter-assay coefficients of variation at 0.026 pmol
tube-' were 6.9% (n = 14) and 8.3% (n = 12), respectively.
Cross-reactivities of fragments of PTHrP and PTH were
determined with comparison of the amounts of peptide which
inhibited 50% of the labelled antigen binding (Table I). The
cross-reactivity of PTHrP(I -141) was taken as 100%. The
results indicated that the antibody recognition characteristics
of this RIA for PTHrP(l - 141) were about one-fourth of that
for PTHrP(I-34); a similar observation was reported pre-
viously (Budayr et al., 1989b). The present data also revealed
that the antiserum used in this study recognised mainly the
amino-terminal portion (1-20) of PTHrP. Furthermore,
human PTH (1-84) and (1-34) did not crossreact in this
assay indicating its specificity for PTHrP molecules.254 Y. MIYAKE et al.
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Figure 1 Northern blot analyses for PTHrP mRNA A and
P-actin mRNA B. Poly(A)+ RNA (5fig) was prepared from seven
tumour xenografts. Five tumours were associated with hypercal-
caemia (a, KEsC-2; b, FA-6; c, Lu-61; d, SEKI; e, Lu-65A) and
two with normocalcaemia (f, MIA PaCa-2; g, PLC/PRF/5).
rRNAs (28S and 18S) were used as size markers.















aThe amount ofsynthetic peptide that inhibits the binding oflabelled
antigen by 50% in a molar ratio wasdetermined bydefining theactivity
ofPTHrP(1
-141) as 100%.
Table II Plasma calcium levels in tumour-bearing nude mice and
PTHrP levels in tumour tissues and culture media
Plasma Caa
(mg dl-') Tumour tissues Culture media
mean±s.d. IR-PTHrPc BIO-PTHrPd IR-PTHrP
Tumour (n =5) (pmolg ) (%) (pmol24 h)
KEsC-2 12.3± 1.50b 57.0 380 450.0
FA-6 11.8± 1.60b 48.0 280 45.0
SEKI 11.1 ±0.73b 26.0 240 3.6
Lu-61 11.2±0.80b 20.0 170 NTf
Lu-65A 11.1±0.92b 15.0 160 3.0
MIA PaCa-2 8.2±0.32 < 1.2 100 <0.6
PLC/PRF/5 8.8±0.30 < 1.2 90 <0.6
'Calcium. bp<0.05 whencomparedwiththelevel ofnottransplanted
nude mice (8.6±0.38, n = 26). cpmol equivalent to PTHrP(1-141) g-
wet weight. dExpressed as percent of cyclic AMP production as
compared with the basal cyclic AMPproduction stimulated bybioassay
medium alone. Basal cyclic AMP production taken as 100%. eThe
amount of IR-PTHrP (pmol) secreted from 1.5 x I09 cells during 24 h.
1.5 x 109 cells are approximately equivalent to 1.5 g wet weight. fNot
tested.
Plasma calcium levels in nude mice bearing tumours
Plasma calcium levels in nude mice bearing KEsC-2, FA-6,
SEKI, Lu-65A and Lu-61 tumours were significantly elevated
compared with levels of both non-transplanted nude mice
and nude mice bearing MIA PaCa-2 and PLC/PRF/5
tumours (Table II).
Northern blot analyses
Northern blot hybridisation for PTHrP mRNA (Figure IA)
revealed that all of the five tumour tissues associated with
hypercalcaemia expressed hybridisable bands. In the two
tumour tissues not associated with hypercalcaemia, no hybri-
disable band was detected. The probe for P-actin mRNA
revealed a band with almost similar intensity in every tissue
(Figure 1B) indicating that the amounts of mRNA applied
for the electrophoresis were roughly equal.
IR-PTHrP in tumour tissues
The dose-response curves of the extracts prepared from
seven tumour xenografts in nude mice are shown in Figure 2.
Since they were parallel to the dose-response curve of
PTHrP(1-141) in a logit-log plot, these extracts contain
peptides with structural regions recognised by the antibody
against the amino-terminal portion of PTHrP. The amount
of IR-PTHrP in these tumour tissues is shown in Table II.
IR-PTHrP in culture media
IR-PTHrP was detected in the extracts prepared from the
culture media of the four cell lines which caused hypercal-
caemia in nude mice. The dose-response curves were parallel
to that of PTHrP(l-141) (data not shown). The amounts of
IR-PTHrP released into the culture media over 24 h ranged
from 3.0 to 450.0 pmol/1.5 x 109 cells (Table II). IR-PTHrP
was not detected in fresh medium extracts nor in the culture
media of the other two cell lines which did not cause hyper-
calcaemia (Table II).
BIO-PTHrP in tumour tissues
Basal cyclic AMP production averaged 3.2 pmol/1.0 x 105
cells in this bioassay. In the five extracts of tumours
associated with hypercalcaemia, BIO-PTHrP was significantly
elevated ranging from 160 to 380% above basal. Since the
bioactivities were measured at the bottom portion of the





Figure 2 Dose-response curves ofthe extracts prepared from five
tumour xenografts associated with hypercalcaemia and two
associated with normocalcaemia. The standard curve is plotted
on the basis of the amount of PTHrP(1-141) added to the tube
(0), and the dose-response curves are plotted on the basis of the
amount of tissue extract added, which is expressed as the equiva-
lent of mg wet weight of tissue. A, KEsC-2; 0, FA-6; 0, SEKI;

























Figure 3 Gel filtration patterns of three tumour tissue extracts
obtained from tumours associated with hypercalcaemia (a, SEKI;
b, FA-6; c, KEsC-2) and a culture medium extract prepared from
KEsC-2 cells d. PTHrP RIA and bioassay activities were
measured in each fraction. Markers shown at the top are 1251-
human albumin ('25I-HA), PTHrP(1-141), cytochrome C (cyt.
C), PTHrP(1-34) and Na'251 (1251).
standard curve, the values assigned are semi-quantitative.
BIO-PTHrP was not significantly elevated in the two extracts
of tumours not associated with hypercalcaemia.
Gelfiltration studies
Two major IR-PTHrP peaks were detected in tumour tissue
extracts (Figure 3); the larger molecular size (Peak I) eluted
between PTHrP(1-141) and cytochrome C and the smaller
molecular size (Peak II) at the position of cytochrome C.
Peak I in all three tumour tissue extracts contained PTHrP
biological activity. Peak II from FA-6 possessed PTHrP
biological activity while that from KEsC-2 did not.
The gel filtration pattern of immunoaffinity-purified IR-
PTHrP from the culture medium conditioned by KEsC-2
(Figure 3d) was almost the same as that of the tissue extract
prepared from the transplantable tumour of KEsC-2 in nude
mice (Figure 3c).
Discussion
A number of reports have concluded that PTHrP may cause
HHM in animal models (Gkonos et al., 1984; Weir et al.,
1988; Kukreja et al., 1988; Ikeda et al., 1988). However,
Mehdizadeh et al. (1989) insisted that a circulating PTH-like
molecule may not be the sole cause of the hypercalcaemia by
analysing a renal cell carcinoma xenograft in nude mice. In
the present study, five human transplantable tumours induc-
ed hypercalcaemia in nude mice. Tumour origins were oeso-
phageal carcinoma, pancreatic carcinoma, lung carcinomas
and melanoma; these sources cover most types of human
tumours reported to induce HHM (Honda et al., 1988a;
Budayr et al., 1989a; Burtis et al., 1990; Tsuchihashi et al.,
1990). Since none of these tumours developed metastases, it
is reasonable to assume that the hypercalcaemia developed in
tumour-bearing nude mice was induced by the production of
hypercalcaemic factor(s) by tumour tissues, not by bone
metastases. Thus, these tumour xenografts represent a useful
experimental model to study HHM.
All of these transplantable tumours associated with hyper-
calcaemia produced PTHrP. The size of PTHrP mRNA was
in good agreement with our previous data on fresh tumour
tissues from patients with HHM (Honda et al., 1988a,b).
Moreover, both PTHrP RIA and bioassay confirmed the
production of PTHrP in these tumour tissues. These data
indicated a very close relationship between the synthesis of
PTHrP-like peptides and the development of HHM in most
cases of these transplantable tumours, supporting our pre-
vious findings with clinical samples (Tsuchihashi et al., 1990).
Several published reports which examined bioactivity of
PTH-like substances produced by HHM-associated tumours
suggest a molecular size heterogeneity (Burtis et al., 1987;
Moseley et al., 1987; Stewart et al., 1987a,b; Strewler et al.,
1987). Current thinking is that these molecules are likely to
be PTHrP. Gel filtration studies combined with RIA and
bioassay on three tumour tissue extracts revealed at least two
different molecules with PTHrP-like immunological and bio-
logical activity. These results indicated that PTHrP molecules
with a molecular size equal to or greater than cytochrome C
were the major components in these tumour extracts. Also, it
is worth noting that each bioassayable peak contained IR-
PTHrP. Since PTHrP fragments with deletions at the amino-
terminal portion act as potent antagonists for bioactive
PTHrP molecules (Nagasaki et al., 1989), the biologically-
inactive IR-PTHrP peak (KEsC-2) may be a PTHrP-like
molecule missing its amino-terminal portion.
The fact that four out of five tumours associated with
HHM could be maintained as cultured cell lines permitted
analysis of the biochemical characteristics and the amount of
PTHrP released into the culture media. A major form of
immunoaffinity-purified IR-PTHrP released into culture
media from KEsC-2 cells possessed the same molecular size
as that detected in the tumour tissue extract; these findings
suggested that molecules detected in the tumour tissue ex-
tracts were actively secreted and played a major role in
inducing hypercalcaemia. The present study also demonstra-
ted that four tumour cell lines associated with HHM secreted
IR-PTHrP in amounts ranging from 3.0 to 450.0 pmol/1.5 x
109 cells (approximately equivalent to 1.5 g wet weight)
24 h-'. Using osmotic minipumps, we have reported that a
subcutaneous infusion of 1,200 pmol 24 h-I of PTHrP(1 -34)
in nude mice induced a remarkable hypercalcaemia (average
17.7 ± 2.4mg dl-'; Nagasaki et al., 1989). Recently, we
found that a dose of 100 pmol 24 h-' also induced significant
hypercalcaemia (average 10.0 ± 0.34 mg dl-') in the test
animals compared to 8.3 ± 0.3 mg dl-' in the controls (Naga-
saki, K. et al., manuscript in preparation). Therefore, the
amount of PTHrP secreted from KEsC-2 cells and
presumably from FA-6 cells seems to be sufficient to induce
hypercalcaemia. However, it is necessary to remember that
tumour cell size and PTHrP-producing activity in vitro does
not always correlate closely with cell size and activity in vivo.
Thus, to substantiate this claim measurements of plasma
PTHrP levels in the PTHrP-infused hypercalcaemic nude
mice and in tumour-bearing hypercalcaemic animals are
necessary.
Consideration of the two cell lines associated with hyper-
calcaemia, but producing rather small amounts of PTHrP256 Y. MIYAKE et al.
highlights the need to examine another possibility. SEKI, a
melanoma cell line, produces large amounts of transforming
growth factor (TGF)-x (Imanishi et al., 1989). Since TGF-x
possesses bone-resorbing activity (Tashjian et al., 1986), this
growth factor could aggravate PTHrP-induced hypercalcae-
mia in this case. There are a number of compounds with
bone-resorbing activity including prostaglandins, TGF-P, epi-
dermal growth factor, interleukin-la and -1p (Bringhurst et
al., 1986; Tashjian et al., 1986; Linkhart et al., 1989; Sato et
al., 1987; Mundy, 1988). Examination of the production of
these compounds in these transplantable tumours is necessary
to better understand their potential roles in this morbidity in
these animal models. Studies of plasma levels of these com-
pounds, including PTHrP, in tumour-bearing nude mice is
one approach to further our understanding.
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